Skip to Content

FibroGen Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Jan 21, 2011 - FibroGen, Inc. today announced interim results of a phase 1 / 2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor (CTGF), in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer. FG-3019 has been well-tolerated, no dose-limiting toxicities have been observed, and dose escalation continues. The interim results were reported at 2011 Gastrointestinal Cancers Symposium, co-sponsored by The American Society of Clinical Oncology (ASCO), in San Francisco, CA (Abstract #269).

The phase 1 / 2 study is an open-label, single-arm, dose-escalation study to evaluate safety, tolerability, pharmacokinetics and ability of FG-3019 administered every 2 weeks to improve outcomes in chemotherapy-naïve patients with unresectable pancreatic cancer. Therapy with gemcitabine and erlotinib starts at day 15, concomitant with administration of the second dose of FG-3019. A safety monitoring committee determines whether escalation to the next dose level is permitted.

Enrollment in the first 4 dose cohorts (3, 10, 15, and 25 mg/kg FG-3019) is complete, and FG-3019 has been well-tolerated at all doses. Assessments of tumor response measured by CT are made according to Response Evaluation Criteria in Solid Tumors 1.0 (RECIST 1.0) guidelines at baseline and every 8 weeks. For dose cohorts of 15 mg/kg and higher, tumor metabolic activity is measured by PET at baseline and day 14 (prior to administration of chemotherapy). Data from patients in the first 3 dose cohorts (n=17) were reported at the Gastrointestinal Cancers Symposium.

Interim results demonstrated:


  • for the first 3 dose cohorts combined, median overall survival is 9.1 months and median time to progression is 4.7 months with longest overall survival (median 9.4 months) and time to progression (median 7.7 months) observed in the highest dose cohort (15 mg/kg);
  • best response according to RECIST indicated that one patient had a partial response, 9 patients had stable disease, 2 patients progressed, and 3 were not evaluable having discontinued the trial for reasons unrelated to treatment with FG-3019 before CT imaging at week 8;
  • in the highest dose cohort (15 mg/kg) for those patients who were evaluated by PET (n=5), 5 of 5 patients showed reduced metabolic activity in the primary tumor after having received one dose of FG-3019 and prior to initiating chemotherapy; 3 of these 5 patients showed a partial metabolic response (defined as a ‰¥ 15% reduction after a single dose of drug);
  • one patient in the 15 mg/kg cohort who continues on the study at 13.9+ months had a complete metabolic response in the primary tumor and a decrease in the biomarker CA 19-9 from 2400 U/mL to a level sustained below 60 U/mL; and
  • survival was significantly higher for patients with low plasma levels of CTGF at baseline (median overall survival of 10.4 months, n=7) than patients with high levels of CTGF at baseline (median overall survival of 4.1 months, n=7) (p=0.0034).

“The development of safe and effective therapies for patients with pancreatic cancer is critical as chemotherapy has limited benefit in treating this aggressive cancer,” said Albert Koong, M.D., Associate Professor of Radiation Oncology and Radiation Therapy at Stanford University Medical Center and Principal Investigator of the trial. “While these are early results from a small study, we are encouraged that FG-3019 appears to be well-tolerated at all dose levels tested thus far and may be having an effect on suppressing tumor activity as indicated by PET data.”

“Our data suggest that increased exposure to FG-3019 is associated with improved outcomes,” said Frank Valone, M.D., Chief Medical Officer of FibroGen. “The patients with the highest continuous drug exposure did not progress while on drug treatment, and one of these continues on treatment at fourteen months. We are planning to try higher doses of FG-3019 in additional groups of patients.”

Prior Experimental Data Regarding CTGF and Pancreatic Cancer

FG-3019 Inhibits Tumor Growth and Metastasis in Pancreatic Cancer Models

Results from nonclinical models of pancreatic cancer have shown that blocking the expression or activity of CTGF reduces tumor growth and metastasis:


  • In a study led by Amato Giaccia, Ph.D., Professor of Radiation Oncology and Radiation Biology at Stanford School of Medicine, researchers demonstrated that CTGF expression levels were elevated in pancreatic tumors, prompting further study of human pancreatic cancer cells that were engineered in the lab to express high levels of CTGF. When implanted into mice, these high-CTGF-expressing cells caused increased tumor growth in mice resulting from more cell proliferation and less apoptosis ("programmed" cell death, which is normally observed in diseased cells). The scientists also reported that tumor growth by the engineered cancer cells could be inhibited by FG-3019.1
  • In another study of FG-3019, researchers at Dartmouth Medical School led by Murray Korc, M.D., Professor of Pharmacology and Toxicology and Chair of Medicine, implanted human pancreatic cancer cells into the pancreas of mice and treated them with FG-3019 two weeks after implantation. At the end of the six-week study, mice treated with FG-3019 exhibited decreased tumor growth and metastasis compared to control mice.2

Genetic Blockade of CTGF Blocks Tumor Growth


  • In another study led by Dr. Giaccia, pancreatic tumor growth in mice was completely prevented by blocking the expression of CTGF in tumor cells. Additionally, animals implanted with tumor cells expressing lower levels of CTGF survived longer than those implanted with tumor cells expressing high levels of CTGF.3

“We believe FG-3019 represents a unique approach to the treatment of pancreatic cancer as it appears that CTGF plays an important role in pathogenesis of pancreatic cancer,” said Thomas B. Neff, Chief Executive Officer of FibroGen. “Therapies designed to blockade CTGF, such as FG-3019, may beneficially act on the tumor as well as reduce desmoplastic tissue development and stromal-tumor signaling.”

Mr. Neff added: “With FG-3019 currently in three phase 2 studies – liver and lung fibrosis and pancreatic cancer – we believe we are in a good position to demonstrate first proof-of-concept for anti-CTGF therapy in modifying the natural course of progression for these life-threatening diseases. Each study addresses critical unmet medical needs.”

CTGF in Desmoplastic Cancers

The role of CTGF as the central mediator of tissue remodeling and fibrosis (persistent and excessive scarring) is well-established in the scientific literature. Several recent studies also implicate CTGF in tumor progression, including tumor cell survival and metastasis, in which CTGF is a key link in the communication between tumor cells and their stroma (the area surrounding the tumor) during the desmoplastic reaction. Desmoplasia involves the formation and proliferation of fibroblasts (cells that produce fibers and structural elements found in the extracellular matrix) and of fibrous connective tissue around the growing cancer. Elevated CTGF levels have been detected in a number of late-stage desmoplastic cancers besides pancreatic cancer,4,5,6 including breast cancer, as well as glioblastoma and sarcomas. CTGF has also been shown to promote epithelial to mesenchymal transition (EMT),7 a process whereby normal epithelial cells become migratory, matrix-producing fibroblasts, shown to be important during invasion and metastasis.8

About Pancreatic Cancer

Pancreatic cancer is one of the deadliest forms of cancer, claiming the lives of approximately 35,000 individuals in the US every year. Incidence rates are similar to mortality rates. Typically, diagnosis of pancreatic cancer is made at an advanced stage when tumors cannot be completely removed by surgery. For years, the chemotherapy agent gemcitabine, used alone or in combination with other drugs, has been the standard of care, but, despite therapy, patients survive only about 6 months from time of diagnosis, and a survival time of only 2 to 4 months in the absence of treatment.

About the FG-3019 Development Program

FG-3019 is a fully human therapeutic antibody designed to inhibit the activity of connective tissue growth factor (CTGF), a matricellular protein that modulates the activity of growth factors, adhesion molecules, integrins, and extracellular matrix. FG-3019 has been the subject of clinical studies involving 125 patients to date. Two phase 2 studies of FG-3019 are ongoing in patients with advanced liver fibrosis due to chronic infection with hepatitis B virus and idiopathic pulmonary fibrosis. Duration of treatment with FG-3019 has been up to 13 months. FG-3019 has been well-tolerated in clinical studies to date with no adverse drug reactions.

About FibroGen, Inc.

FibroGen, Inc. was founded to discover and develop anti-fibrotic therapeutics. Using its expertise in the field of tissue fibrosis, in particular with matricellular proteins such as CTGF, and matrix assembly enzymes such as prolyl hydroxylases, FibroGen now is engaged in clinical development of anti-CTGF therapy and prolyl hydroxylase inhibitors for serious unmet medical needs. Current and planned clinical trials of FG-3019 will study the potential of anti-CTGF therapy to reverse liver and lung fibrosis and to improve clinical outcomes in pancreatic cancer. From its large proprietary library of prolyl hydroxylase inhibitors, FibroGen is developing multiple prolyl hydroxylase inhibitors designed to selectively activate HIF biology for the treatment of anemia, and elicit a rapid, multi-factorial, cytoprotective response for treating or preventing conditions resulting from acute ischemic injury and/or inflammation, including cardioprotection and inflammatory bowel disease, among others. FibroGen also develops and produces recombinant human collagens and gelatins using proprietary production technology that permits making collagen essentially identical to the native protein. Development of medical devices, such as corneal implants fabricated with recombinant human collagen Type III, is ongoing.

For more information about FibroGen, Inc., please visit


1.   Dornhöfer N, et al. Connective tissue growth factor specific mAb therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2006; 66:5817-27.
2.   Aikawa T, et al. Connective tissue growth factor specific antibody attenuates tumor growth, metastasis and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. Cancer Ther. 2006 May;5(5):1108-16.
3.   Bennewith K, et al. The role of tumor-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 2009; 69:775-784.
4.   Wenger, C, et al. Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 1999; 18:1073-1080.
5.   Ryu, B., et al. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res. 2001; 61:1833-1838.
6.   Iacobuzio-Donahue C.A., et al. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol. 2002 Jan;160(1):91-9.
7.   Burns WC, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol. 2006 Sep;17(9):2484-94.
8.   Yang J and Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008 Jun;14(6):818-29.

Contact: Contact for Media
FibroGen, Inc.
Laura Hansen, Ph.D., 415-978-1433



Posted: January 2011